References
- Jabbour E, Kantarjian H. Introduction: chronic myelogenous leukemia (CML). Semin Hematol 2007;44(Suppl. 1):S1–S3.
- Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–293.
- Baccarani M, Cortes J, Pane F, . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
- Druker BJ, Guilhot F, O'Brien SG, . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
- Ries LAG, Smith MA, Gurney JG, . Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. 1999. Available from: http://seer.cancer.gov/publications/childhood/
- Champagne MA, Capdeville R, Krailo M, . Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004;104:2655–2660.
- Millot F, Guilhot J, Nelken B, . Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187–192.
- Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program 2010:368–376.
- O'Brien SG, Guilhot F, Larson RA, . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
- Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008;93:161–169.
- Hughes T, Deininger M, Hochhaus A, . Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.
- Branford S, Fletcher L, Cross NC, . Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330–3338.
- Müller MC, Erben P, Saglio G, . Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008;22:96–102.
- Kantarjian HM, Deisseroth A, Kurzrock R, . Chronic myelogenous leukemia: a concise update. Blood 1993;82:691–703.
- Millot F, Baruchel A, Guilhot J, . Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011;29:2827–2832.
- El-Alfy MS, Al-Haddad AM, Hamed AA. Management of CML in the pediatric age group: imatinib mesylate or SCT. J Egypt Nat Cancer Inst 2010;22:227–232.
- Champagne MA, Fu CH, Chang M, . Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011;57:56–62.
- Sokal JE, Cox EB, Baccarani M, . Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 1984;63:789–799.